Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 19/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9534159 | 0.88 | HRH4 (1.00) | HRH4HRH3TP53CYP1A2CYP3A4 | |
| Iodophenpropit SCHEMBL114508 | 0.78 | HRH4 (1.00) | HRH4HRH3TP53CYP1A2CYP3A4 | |
| Iodophenpropit SCHEMBL22651297 | 0.78 | HRH4 (1.00) | HRH4HRH3TP53CYP1A2CYP3A4 | |
| Iodophenpropit SCHEMBL30632137 | 0.77 | HRH4 (1.00) | HRH4HRH3TP53CYP1A2CYP3A4 | |
| SCHEMBL8618191 | 0.77 | HRH3 (0.62) | HRH4HRH3TP53CYP1A2CYP3A4 | |
| Clobenpropit SCHEMBL19733457 | 0.75 | HRH4 (0.65) | HRH4HRH3TP53CYP1A2CYP3A4 | |
| SCHEMBL9533886 | 0.72 | HRH4 (0.58) | HRH4HRH3TP53CYP1A2CYP3A4 | |
| SCHEMBL2741604 | 0.70 | HRH4 (0.68) | HRH4HRH3 | |
| SCHEMBL194703 | 0.68 | HRH3 (0.71) | HRH4HRH3 | |
| SCHEMBL1334244 | 0.68 | HRH3 (1.00) | HRH4HRH3TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2768 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673146-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | Biohaven Therapeutics Ltd. (VG) | 2026-01-07 | — | — | EP | claimed |
| US-20250085273-A1 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2025-03-13 | — | — | US | claimed |
| US-20240415789-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | TONIX PHARMA LIMITED (IE) | 2024-12-19 | — | — | US | claimed |
| WO-2024182465-A2 | METHODS FOR TREATING OBSESSIVE COMPULSIVE RELATED DISORDERS, TIC DISORDERS AND GLUTAMATE EXCITOTOXICITY RELATED DISORDERS | ALCO THERAPEUTICS, LLC (US) | 2024-09-06 | — | — | WO | claimed |
| EP-4412602-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | Tonix Pharmaceuticals Holding Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| US-20240261459-A1 | BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSURE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | claimed |
| US-11896724-B2 | Bioactive polymeric dressing for accelerated wound closure | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-02-13 | — | — | US | claimed |
| US-11857600-B2 | GPCR heteromer inhibitors and uses thereof | GPCR THERAPEUTICS, INC. (KR) | 2024-01-02 | — | — | US | claimed |
| EP-4294446-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | Agonex Biopharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230390215-A1 | SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY | AGONEX BIOPHARMACEUTICALS, INC. | 2023-12-07 | — | — | US | claimed |
| WO-2002072542-A2 | PH-DEPENDENT NMDA RECEPTOR ANTAGONISTS | EMORY UNIVERSITY (US) | 2002-09-19 | — | — | WO | claimed |
| WO-2002064212-A1 | METHOD AND COMPOSITIONS FOR REDUCING CARDIAC DYSFUNCTIONS WITH A SELECTIVE HISTAMINE H3 RECEPTOR AGONIST | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-08-22 | — | — | WO | claimed |
| CN-1329490-A | Composition and method for treating allergic diseases | SCHERING CORP (US) | 2002-01-02 | — | — | CN | claimed |
| EP-1117405-A2 | COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES | SCHERING CORPORATION (US) | 2001-07-25 | — | — | EP | claimed |
| US-6103735-A | IN COMBINATION, ANTAGONISTS OF A NEUORKININ, A HISTAMINE 3 AND A HISTAMINE 1; ANTIALLERGENS; RHINITIS, ASTHMA AND RELATED DISORDERS; COUGH, WHEEZING; SNEEZING, ITCHING, RUNNY NOSE, NASAL CONGESTION, REDNESS OF THE EYE, TEARING | SCHERING CORPORATION (US) | 2000-08-15 | — | — | US | claimed |
| WO-2000021512-A2 | COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES | SCHERING CORPORATION (US) | 2000-04-20 | — | — | WO | claimed |
| CN-1233179-A | Treatment of upper airway allergic responses with a combination of histamine receptor antagonists | SCHERING CORP (US) | 1999-10-27 | — | — | CN | claimed |
| EP-0920315-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1999-06-09 | — | — | EP | claimed |
| US-5869479-A | ADMINISTERING HISTAMINE H1 RECEPTOR ANTAGONISTS AND HISTAMINE H3 RECEPTOR ANTAGONISTS; NASAL DECONGESTANT WITHOUT THE NERVOUS SYSTEM OR CARDIOVASCULAR SIDE EFFECTS | SCHERING CORPORATION (US) | 1999-02-09 | — | — | US | claimed |
| WO-1998006394-A1 | TREATMENT OF UPPER AIRWAY ALLERGIC RESPONSES WITH A COMBINATION OF HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-19 | — | — | WO | claimed |